
Research · Perspectives
Prostate Cancer in 2026: Personalizing ADT Duration, PARP Inhibitors Move Earlier, and a Bispecific That May Finally Crack Immunotherapy in This Disease
By Li Zhang, MD
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER


2025-08-22

2025-08-22